A Phase II Study of Gemzar, Taxotere, and Xeloda (GTX) for Adjuvant Pancreatic Cancer.

Trial Profile

A Phase II Study of Gemzar, Taxotere, and Xeloda (GTX) for Adjuvant Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Oct 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 29 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top